Akeso’s lung cancer drug reduces death risk by 34%, marking the first Chinese drug at ASCO’s top stage in 61 years

Akeso’s Clinical Trial Results for Ivonescimab in Advanced Lung Cancer

Akeso, the Chinese biotechnology company whose drug ivonescimab was hailed as “biotech’s DeepSeek moment” last year, has released phase three clinical trial data. The results show a 34% reduction in the risk of death among patients with advanced squamous non-small cell lung cancer.

The data, filed with the Hong Kong stock exchange on Monday and selected for presentation at the American Society […], highlights a significant advancement in cancer treatment.

This story continues at The Next Web.